ValiRx PLC Shareholder Circular and Notice of General Meeting (4819Y)
December 06 2017 - 2:00AM
UK Regulatory
TIDMVAL
RNS Number : 4819Y
ValiRx PLC
06 December 2017
VALIRX PLC
("ValiRx" or "the Company")
SHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING
London, UK, 6 December 2017: ValiRx Plc (AIM: VAL), a clinical
stage biotechnology announces that it has recently published and
posted to shareholders a circular and notice convening a General
Meeting of ValiRx Plc to be held at the offices of DAC Beachcroft
LLP at 100 Fetter Lane, London EC4A 1BN at 9:00 a.m. on 21 December
2017.
The directors will propose at the General Meeting shareholder
resolutions seeking shareholder authority to allot shares and the
dis-application of pre-emptive rights.
A copy of the Circular will be available on the Company's
website shortly: www.valirx.com
- ENDS -
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka, Chief Executive www.valirx.com
Tarquin Edwards, Investor Relations Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 0880
Liam Murray / Jo Turner
Beaufort Securities Limited (Broker) Tel: +44 (0) 20 7382 8300
Jon Belliss
Notes for Editors
About ValiRx Plc
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTABRTMBJMBJR
(END) Dow Jones Newswires
December 06, 2017 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024